Cargando…
Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies
BACKGROUND: Autoimmune encephalitis (AE) with neuronal surface antibodies (NSAbs) presents pathogenesis mediated by B cell-secreting antibodies. Rituximab is a second-line choice for the treatment for AE with NSAbs, which can cause B cell depletion via targeting CD20. However, the optimal protocol a...
Autores principales: | Du, Ying, Zhao, Chao, Liu, Juntong, Li, Chuan, Yan, Qi, Li, Lin, Hao, Yunfeng, Yao, Dan, Si, Huaxing, Zhao, Yingjun, Zhang, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587594/ https://www.ncbi.nlm.nih.gov/pubmed/36273158 http://dx.doi.org/10.1186/s12974-022-02622-8 |
Ejemplares similares
-
Correction: Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies
por: Du, Ying, et al.
Publicado: (2022) -
Rituximab for Autoimmune Encephalitis with Epilepsy
por: Kurukumbi, Mohankumar, et al.
Publicado: (2020) -
Case Report: The Use of Rituximab in Antibody-Negative Autoimmune Encephalitis
por: Park, Soo-Hyun, et al.
Publicado: (2021) -
Clinical and Electroencephalographic Features of the Seizures in Neuronal Surface Antibody-Associated Autoimmune Encephalitis
por: Wang, Yan, et al.
Publicado: (2020) -
Evaluation of CSF albumin quotient in neuronal surface antibody-associated autoimmune encephalitis
por: Lai, Qi-Lun, et al.
Publicado: (2022)